A purple and pink letter v on a white background.
February 28, 2020

What is ARTAS iX™?

The Market Report states that the Global Hair Restoration Services Market size is expected to rise to new levels at a compound annual growth rate of 5.4%, reaching $11.9 billion by 2025. It is indicative that hair restoration has steadily become a popular aesthetic procedure. The treatment is usually sought after by men who suffer from one or more kinds of extreme hair loss or hair thinning. The case for hair loss is primarily attributed to genetic factors and age and is mostly prevalent in males.

With the demand for hair restoration accelerating in growth, ARTAS iX™ is well-poised to help you capitalize on this lucrative market. ARTAS iX™ Robotic Hair Restoration System is the most intelligent solution to hair loss, utilizing the Follicular Unit Extraction (FUE) method it offers a precise and minimally invasive procedure for patients. The system is able to perform repeatable harvesting with simultaneous recipient site-making and implantation, utilizing state-of-the-art robotic and artificial intelligence technology, in one compact platform.

Why Choose FUE?

Hair restoration procedures fall into two categories: Follicular Unit Transplantation (FUT) and Follicular Unit Extraction (FUE). Both methods consist of removing hair follicles from the back of the head, better known as the donor area. The primary difference between these two methods is that with FUT, the surgeon removes a strip of skin from the donor area, and then proceeds to extract individual follicular units. With FUE, these very follicular units are individually removed. The latter leaves no linear scar, making it easy to return to daily activities relatively sooner. According to the American Academy of Dermatology (AAD), FUE is growing 39% annually as FUT becomes less popular. The FUE process is quickly gaining momentum as the future of hair restoration as it tackles many pre-existing apprehensions regarding hair restoration such as scars and extensive downtimes.

What makes ARTAS iX™ different?

ARTAS iX™ is a proprietary, patented, and FDA-cleared robotic hair restoration system. The advanced multi-camera stereoscopic vision system with 44-micron resolution and 7-axis robot arm delivers unmatched intelligence, precision, repeatability, and clinical efficiency.

It intelligently analyzes and selects grafts from the donor area with no risk of linear scarring while accurately identifying and creating optimal recipient sites. The existing terminal hair is protected throughout the procedure along with a natural appearance in the donor and implantation areas.

Furthermore, the 3D pre-operative planning feature enables physicians to customize and prescribe the hairline design with the desired angle, direction and density. Given that hair restoration procedures take time, the compact and streamlined ergonomic design makes it easy to use while minimizing the footprint and facilitating clinical efficiency.

How can ARTAS iX™ benefit your business? 

The male aesthetics market remains largely untapped with 1.2 billion men, worldwide, suffering from hereditary baldness. This represents an extraordinary opportunity to capture both new patients and new revenue streams for physicians. The ARTAS procedure provides a unique platform to capitalize on this lucrative market size. The American Society of Aesthetic Plastic Surgery (ASAPS) stated that 10% of cosmetic surgeries were performed on males in 2015 with hair restoration being one of the most popular. The ARTAS iX™ Robotic Hair Restoration System uniquely positions your practice as a leader in providing the most advanced technology in hair restoration, thus driving significant revenue opportunities.

For any practice owner looking to launch a hair restoration business, investing in the right equipment is a major decision in the overall process. Learn more about the ARTAS iX™ robotic hair restoration system —contact a Venus Concept expert today using the button below.

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.